Blog Posts
Q2 2026 Highlights – Partnership for the U.S. Life Science Ecosystem (PULSE)
PULSE continues to build awareness of the unique and fundamental role of life sciences mergers and acquisitions (M&A) and other pro-competitive partnerships. Read below for a round-up of recent PULSE updates and commentaries. Advocating for Balanced Competition...
States Must Preserve Balanced Approach to Life Sciences Antitrust Enforcement
Policymakers in California, New York and across the country are considering state-level antitrust proposals that could chill innovation, competition and growth in key industries, including life sciences.
PULSE Urges FTC, DOJ to Support Pro-Competitive Life Sciences Collaborations and M&A
In recent comments to the Department of Justice (DOJ) and Federal Trade Commission (FTC), PULSE highlighted critical reforms to ensure that U.S. competition policies support – and do not impede – the pro-competitive mergers and acquisitions (M&A) and other collaborations that drive American life sciences innovation.
Q&A with PULSE Partner BioNJ on the Local Impact of Life Sciences M&A
PULSE recently sat down for a conversation on life sciences M&A with Debbie Hart, President and CEO at BioNJ, the life sciences trade association for New Jersey.
By the Numbers: Citeline’s R&D Annual Review Underscores Importance of Life Sciences M&A
Findings from Citeline’s latest report, Pharma R&D Annual Review 2026, highlight the continued U.S. leadership in the life sciences ecosystem.
ICYMI: ITIF Report Underscores the Importance of Balanced Antitrust Enforcement
A recent report from the Information Technology and Innovation Foundation (ITIF), “Antitrust Undone: How Competition Enforcers Are Undermining Competition,” highlights the risks of unnecessarily aggressive antitrust enforcement in innovative industries. The report cautions that such policies could, “adversely impact U.S. global competitiveness and innovative dynamism.”
Innovations Advanced by M&A: A New Treatment for Hyperkalemia
AstraZeneca’s acquisition of ZS Pharma helped bring a treatment for hyperkalemia to patients globally.
M&A Is Essential to Sustaining Life Sciences Momentum in 2026
Life sciences M&A activity gained momentum in late 2025, and that acceleration is expected to continue in 2026. This positive trend is vitally important for the many treatments and cures that depend on these partnerships to reach patients.
ICYMI: Congressional Briefing Spotlights Value of Life Sciences M&A
New research presented at a Congressional staff briefing highlighted the strong, positive relationship between pharmaceutical mergers and acquisitions (M&A) and the launches of new drugs for patients. Research Finds that Pharmaceutical M&A Drives New, Novel...
2H 2025 Highlights – Partnership for the U.S. Life Science Ecosystem (PULSE)
This year, life sciences mergers and acquisitions (M&A) played a crucial role in driving innovation and supporting America’s global leadership in the life sciences.